Activation of necroptosis pathway in podocyte contributes to the pathogenesis of focal segmental glomerular sclerosis
Related Experiment Video
Updated: Sep 2, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Haoqiang Hu1,2, Mengyuan Li2, Binfeng Chen2
1Department of Nephrology, Affiliated Dongguan People's Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523000, China.
Background:
Focal segmental glomerulosclerosis (FSGS) is characterized by podocyte damage and severe proteinuria. The exact mechanism of podocyte damage and loss remains unclear. Necroptosis, a lytic form of programmed cell death mediated by RIP3 and MLKL, has emerged as an important cell death pattern in multiple tissues and cell types. Necroptosis in FSGS has not been investigated.
Methods:
Public GEO data regarding podocyte treated with vehicle or adriamycin (ADR) was identified and analyzed. Cultured human podocytes were used to explore the activation of necroptosis upon ADR stimulation. The expression of necroptosis pathway molecules, p-RIP3 and p-MLKL, was examined in the glomeruli and defoliated urinary podocytes of patients with FSGS. The effect of necroptosis inhibition was assessed in ADR-induced glomerulopathy mice using GSK872.
Results:
Publicly available RNA-sequencing data analysis showed that both necroptosis and NLRP3 inflammasome pathway were up-regulated in ADR-injured podocyte. Immunofluorescent staining showed increased expression of p-RIP3 and p-MLKL, the active forms of RIP3 and MLKL, in podocytes of FSGS patients and ADR-induced glomerulopathy mice but not in the normal control. GSK872, an RIP3 kinase inhibitor, significantly inhibited the expression of p-RIP3, p-MLKL and activation of NLRP3 in cultured podocytes treated with ADR. GSK872 treatment of mice with ADR-induced nephropathy resulted in the reduced expression of p-RIP3, p-MLKL, NLRP3 and caspase-1 p20. GSK872 also significantly inhibited the expression of p-MLKL in the podocytes of ADR-induced nephropathy, resulting in the attenuation of proteinuria and renal histological lesions.
Conclusion:
Necroptosis pathway might be a valuable target for the treatment of FSGS.
Insights
Necroptosis, a programmed cell death pathway, is activated in focal segmental glomerulosclerosis (FSGS). Inhibiting necroptosis reduced kidney damage and proteinuria in a mouse model, suggesting it as a potential therapeutic target for FSGS.
Area of Science:
- Nephrology
- Cell Biology
- Molecular Medicine
Background:
- Focal segmental glomerulosclerosis (FSGS) is characterized by podocyte injury and proteinuria, with unclear underlying mechanisms.
- Necroptosis, a form of programmed cell death involving RIP3 and MLKL, is a significant cell death pathway not previously studied in FSGS.
Purpose of the Study:
- To investigate the role of necroptosis in FSGS pathogenesis.
- To explore necroptosis as a potential therapeutic target for FSGS.
Main Methods:
- Analysis of public GEO data and cultured human podocytes stimulated with adriamycin (ADR).
- Examination of necroptosis markers (p-RIP3, p-MLKL) in FSGS patients and ADR-induced nephropathy mice.
- Assessment of necroptosis inhibition using GSK872 in vitro and in vivo.
Main Results:
- ADR-injured podocytes showed upregulated necroptosis and NLRP3 inflammasome pathways.
- Active necroptosis markers (p-RIP3, p-MLKL) were elevated in FSGS patients and ADR-induced mice.
- GSK872 treatment reduced necroptosis, NLRP3 activation, and attenuated proteinuria and kidney lesions in mice.
Conclusions:
- The necroptosis pathway is implicated in FSGS development.
- Inhibition of necroptosis shows promise in ameliorating FSGS.
- Targeting necroptosis may offer a novel therapeutic strategy for FSGS.
Related Concept Videos
Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
The Extrinsic Apoptotic Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Nephrotic Syndrome I : Introduction
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Acute Kidney Injury II: Pathophysiology

